Mirxes, a spin-off of Singapore ’s Agency for Science, Technology and Research, will establish a foothold in Hong Kong this year to tap into the vast multi-cancer early-stage screening market in the Greater Bay Area.
Big Chinese pharmaceutical firms with a track record of profits will be key beneficiaries of China reopening, with pre-revenue biotechnology companies falling out of favour, Citigroup says.